Evidence-based treatment of systemic lupus erythematosus and its complications

Abstract

Outcomes for patients with systemic lupus erythematosus (SLE) have improved during the last two decades as our understanding of the disease expands. In particular, the importance of antimalarial therapy for  addressing and preventing a host of complications in SLE has emerged. Furthermore, evidence is mounting that corticosteroids, while offering excellent control of disease activity, are responsible for many of the late complications of SLE and need to be prescribed in modest doses for the shortest time possible. To achieve  this, an understanding of the available ‘steroid-sparing’ immunosuppressants is useful. Specific attention needs to be paid to the two most important complications of SLE, i.e. infections and atherosclerotic  cardiovascular events. Awareness of, screening for and aggressive management of risk factors for these comorbidities are paramount.